Product Images Irinotecan Hydrochloride

This is a graph for a study (Study 2) comparing the survival rate between two treatments: Irinotecan/5-FU/LV and 5-FULV. The x-axis shows the number of months after treatment, and the y-axis represents the probability of survival. The log-rank test was used to compare the two treatments.*

This is a figure showing survival data for a study (Study 7) comparing second-line Irinotecan treatment to Best Supportive Care (BSC) for patients with a certain condition. The figure displays the number of patients in each group (189 for Irinotecan and 90 for BSC), the median follow-up time (13 months), and the median survival time (9.2 months for Irinotecan and 6.5 months for BSC). Additionally, the figure shows a statistical test (log-rank) with a p-value of 0.0001 indicating a significant difference in survival between the two treatments.*

This is a product description of Irinotecan Hydrochloride Injection, USP, a cytotoxic agent used for intravenous use. The 100mg/5mL single-dose vial must be diluted before use. The product is manufactured by Ingenus Pharmaceuticals and comes in a 2mg/mL concentration, and should be stored properly to prevent freezing. Contact information for the manufacturer is provided.*